Results 71 to 80 of about 71,753 (234)

Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder

Addiction Science & Clinical Practice
Background Medications for opioid use disorder (MOUD) are among the best tools available to combat the opioid epidemic. Yet, use of MOUD among people with opioid use disorder (OUD) remains low.
Nicholas C. Cardamone, Rebecca E. Stewart, Kyle M. Kampman, Steven C. Marcus   +3 more
doaj   +1 more source

Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Cannabidiol (CBD), the main non‐intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP‐mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol ...
Andriy A. Gorbenko, Titiaan E. Post, Pamela K. Strugala, Erica S. Klaassen, Linda E. Klumpers, Saco J. de Visser, Cristina Sempio, Jost Klawitter, Jules A. A. C. Heuberger, Geert J. Groeneveld   +9 more
wiley   +1 more source

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source

Contemporary and Emerging Therapies in the Management of Refractory Angina: A Clinical Review

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Refractory angina (RA) represents a growing challenge in clinical cardiology, particularly in patients with obstructive coronary artery disease (CAD) who remain symptomatic despite optimal medical therapy and who are not candidates for revascularization.
Alex Angers‐Goulet, Siddhartha Mengi, David Garcia Labbé, Can Manh Nguyen, Jean‐Michel Paradis   +4 more
wiley   +1 more source

Easier, Safer, and Greener: Unlocking the Power of Solid Reagents in Organic Reactions by Mechanochemistry

ChemistryEurope, EarlyView.
This review highlights the powerful synergy between mechanochemistry and solid reagents to replace hazardous substances traditionally used in organic synthesis. Such an approach offers a safer and more sustainable pathway for conducting organic reactions, with potential benefits in both reactivity and selectivity. The use of solid bases, acids, and gas
Adrien Gallego, Nicolas Pétry, Julien Pinaud, Olivia Giani, Frédéric Lamaty   +4 more
wiley   +1 more source

Emerging neuromodulation treatments for opioid and stimulant use disorders

Frontiers in Human Neuroscience
Over the past decade, deaths attributable to opioid and stimulant use have risen dramatically. While the U.S. Food and Drug Administration (FDA) has approved three medications for opioid use disorder, there is currently no FDA-approved treatment for ...
Susanna D. Howard, Liming Qiu, Nathan Hager, Anna Rose Childress, Casey H. Halpern, Katherine W. Scangos, Katherine W. Scangos   +6 more
doaj   +1 more source

Association of Early Opioid Withdrawal Treatment Strategy and Patient-Directed Discharge Among Hospitalized Patients with Opioid Use Disorder [PDF]

, 2023
Mohammad Alrawashdeh, Chanu Rhee, Michael Klompas, Marc R. Larochelle, Russell E. Poland, Jeffrey S. Guy, Simeon D. Kimmel   +6 more
openalex   +1 more source

Editorial: Opioids and opioid-use disorders

Frontiers in Pharmacology, 2023
Giordano de Guglielmo, Marsida Kallupi, Andrea Cippitelli, Daniele Caprioli, Daniele Caprioli, Kabirullah Lutfy   +5 more
openaire   +4 more sources

Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta‐Analysis

European Eating Disorders Review, EarlyView.
ABSTRACT Objective To compare the efficacy and safety of lisdexamfetamine, topiramate, and naltrexone/bupropion for treating binge eating disorder (BED) using network meta‐analysis. Method We systematically searched PubMed, Scopus, ClinicalTrials.gov, and Cochrane Central up to February 2025 for randomized controlled trials evaluating these medications
Tamer Hodrob, Ibrahim Ismail, Alaaeddin Abusalameh, Celina R. Andonie, Omar Ayesh, Hazem Ayesh   +5 more
wiley   +1 more source

Editorial: Opioids in the time of the COVID-19 pandemic: from cellular mechanisms to public health policy

Frontiers in Pharmacology, 2023
Scott John, David R. Walwyn, Kathryn DeFea, Tim G. Hales, Wendy Walwyn   +4 more
doaj   +1 more source